Tammaro, Kelly A <br/><br/>
Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa).  [electronic resource] 

 -  Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners  Sep 2005 
 - 127-30 p.  digital 
<br/><br/> Publication Type: Case Reports; Journal Article 
<br/><br/><label>ISSN: </label>1078-1552 
<br/><br/><label>Standard No.: </label>10.1191/1078155205jp158cr  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Erlotinib Hydrochloride<br/>Gefitinib<br/>Humans<br/>Lung Diseases, Interstitial--chemically induced<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Protein Kinase Inhibitors--adverse effects<br/>Quinazolines--adverse effects<br/>Tomography, X-Ray Computed